AIMCA
PTGX icon

Alberta Investment Management Corp (AIMCo)’s Protagonist Therapeutics PTGX Stock Holding History

Alberta Investment Management Corp (AIMCo)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,000
Closed -$3.42M – 1345
2021
Q4 		$3.42M Buy
+100,000
New +$3.16M 0.02% 516

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Alberta Investment Management Corp (AIMCo)'s PTGX Position: Q1 2022 in Review

Alberta Investment Management Corp (AIMCo) sold out of Protagonist Therapeutics (PTGX) in Q1 2022, closing a stake of 100,000 shares — an estimated $3.42M sold.

Alberta Investment Management Corp (AIMCo) first reported a position in PTGX in Q4 2021 and held it in 1 quarter. The position peaked at $3.42M in Q4 2021. 140 funds tracked by Wall St. Rank hold PTGX as of Q1 2022.

  • Alberta Investment Management Corp (AIMCo) reported no remaining Protagonist Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Alberta Investment Management Corp (AIMCo) sold 100,000 Protagonist Therapeutics shares in Q1 2022, an estimated $3.42M.
  • Alberta Investment Management Corp (AIMCo) first reported a position in Protagonist Therapeutics in Q4 2021 and held it in 1 quarter.
  • Alberta Investment Management Corp (AIMCo)'s Protagonist Therapeutics position peaked at $3.42M in Q4 2021.
  • 140 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2022.

Based on Alberta Investment Management Corp (AIMCo)'s 13F filing for Q1 2022, filed 16 May 2022.